This provider's $82.9M in total Medicare payments ranks in the 99th percentile of Clinical Laboratory providers nationally.
This provider's billing patterns fall within normal ranges for their specialty.
AI-generated analysis based on Medicare payment data.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2014 | $27.11 | $21.91 | 1.24x | $5.20 | $13.4M | 612.0K | 22 |
| 2015 | $61.30 | $29.97 | 2.05x | $31.33 | $11.7M | 390.2K | 26 |
| 2016 | $305.19 | $79.60 | 3.83x | $225.59 | $6.5M | 82.2K | 9 |
| 2017 | $307.80 | $102.19 | 3.01x | $205.61 | $9.2M | 90.0K | 6 |
| 2018 | $306.58 | $96.92 | 3.16x | $209.66 | $8.5M | 87.8K | 6 |
| 2019 | $296.91 | $90.34 | 3.29x | $206.57 | $8.4M | 93.4K | 36 |
| 2020 | $280.08 | $89.02 | 3.15x | $191.06 | $6.2M | 69.2K | 46 |
| 2021 | $210.74 | $70.95 | 2.97x | $139.79 | $8.1M | 113.8K | 46 |
| 2022 | $251.81 | $78.06 | 3.23x | $173.75 | $6.2M | 78.9K | 36 |
| 2023 | $290.51 | $84.32 | 3.45x | $206.19 | $4.8M | 56.6K | 36 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 259.6K | $28.0M | $107.88 | 2.32x |
| 80307 | Testing for presence of drug, by chemistry analyzers | 226.8K | $15.0M | $66.07 | 5.22x |
| G0431 | Drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter | 85.5K | $8.3M | $96.82 | 1.81x |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 36.9K | $5.6M | $150.56 | 2.66x |
| G0479 | Drug tests(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers utilizing immunoassay, enzyme assay, TOF, MALDI, LDTD, DESI, DART, GHPC, GC mass spectrometry), includes sample validation when | 41.5K | $3.2M | $77.31 | 4.45x |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 39.1K | $3.0M | $77.80 | 1.93x |
| 83789 | Mass spectrometry (laboratory testing method) | 102.7K | $2.5M | $24.03 | 1.48x |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 9.7K | $1.9M | $194.67 | 2.83x |
| 83925 | Opiates (drug) measurement | 74.4K | $1.7M | $23.16 | 1.09x |
| G6056 | Opiate(s), drug and metabolites, each procedure | 59.7K | $1.5M | $25.43 | 1.51x |
| 82542 | Chemical analysis using chromatography technique | 55.7K | $1.3M | $24.01 | 1.63x |
| 83788 | Mass spectrometry (laboratory testing method) | 49.5K | $1.2M | $24.05 | 1.50x |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | 31.5K | $786.7K | $24.96 | 3.01x |
| 82649 | Dihydromorphinone (drug) level | 21.3K | $728.2K | $34.22 | 1.18x |
| 83840 | Methadone level | 30.9K | $672.0K | $21.74 | 1.19x |
| G6046 | Dihydromorphinone | 19.1K | $649.8K | $34.11 | 1.30x |
| G6053 | Methadone | 29.2K | $632.7K | $21.69 | 1.97x |
| 82520 | Cocaine (drug) level | 29.3K | $590.7K | $20.19 | 1.19x |
| 82646 | Dihydrocodeinone (drug) measurement | 21.3K | $585.0K | $27.49 | 1.18x |
| G6044 | Cocaine or metabolite | 28.6K | $576.7K | $20.14 | 2.11x |
This provider submits charges 2.74 times higher than what Medicare actually pays.
A markup ratio of 2.74x means for every $100 Medicare pays, this provider initially charges $274. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in RI for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| East Side Clinical Laboratory, Inc. | East Providence, RI | $58.3M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data